Related Experiment Videos
Rilmenidine in the hypertensive type-2 diabetic: a controlled pilot study versus captopril
B Bauduceau1, H Mayaudon, O Dupuy
1Service d'endocrinologie, Hôpital d'Instruction des Armées Bégin, Saint Mandé, France.
Journal of Cardiovascular Risk
|April 29, 2000
Summary
Rilmenidine and captopril similarly reduced blood pressure and microalbuminuria in patients with hypertension and type-2 diabetes. Rilmenidine
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Rilmenidine is an innovative antihypertensive agent targeting I1 imidazoline receptors.
- Rilmenidine has demonstrated antihypertensive efficacy in type-2 diabetics with good tolerance.
Purpose of the Study:
- To compare the effects of rilmenidine and captopril on microalbuminuria progression.
- To evaluate antihypertensive efficacy in hypertensive type-2 diabetics.
Main Methods:
- A 6-month, double-blind, randomized, controlled study.
- Compared rilmenidine and captopril in patients with hypertension, type-2 diabetes, and microalbuminuria.
Main Results:
- Both rilmenidine and captopril similarly reduced blood pressure and microalbuminuria.
- No significant changes in creatinine clearance or glycosylated hemoglobin levels were observed.
- Clinical and laboratory acceptability were comparable for both treatments.
Conclusions:
- Rilmenidine shows similar antihypertensive effects to captopril in hypertensive type-2 diabetics.
- Rilmenidine effectively decreases microalbuminuria, suggesting potential nephroprotective effects.
- The study supports rilmenidine as a viable treatment option for this patient population.